Novo Nordisk shares slide after Ozempic pill fails
Novo Nordisk shares slumped over 10% after its Ozempic pill failed to slow Alzheimer's progression in major trials. Read the latest on the pharmaceutical giant's market struggles.
Category : Search result: Novo Nordisk
Novo Nordisk cuts forecasts again as drug demand slows
Danish pharmaceutical giant Novo Nordisk has cut its sales and profit forecasts for the second time in three months, sending shockwaves through the healthcare sector as demand for its blockbuster weight-loss drugs shows signs of slowing.
Novo Nordisk Bids for Metsera, Challenging Pfizer's Offer
Danish pharmaceutical giant Novo Nordisk has entered a bidding war with Pfizer for obesity-focused biotech firm Metsera, potentially disrupting the US company's planned acquisition in a major power play for obesity treatment dominance.
Page 1 of 1